

EMLc

ATC codes: L01DA01

| | | |
|--------------------------|---|--------------------|
| Indication | Rhabdomyosarcoma primary site | ICD11 code: 2C25.Z |
| INN | Dactinomycin | |
| Medicine type | Chemical agent | |
| List type | Complementary (EML) (EMLc) | |
| Formulations | Parenteral > General injections > IV: 500 µg in vial powder for injection | |
| EML status history | First added in 1984 (TRS 722) Changed in 2015 (TRS 994) | |
| Sex | All | |
| Age | Also recommended for children | |
| Therapeutic alternatives | The recommendation is for this specific medicine | |
| Patent information | Patents have expired in most jurisdictions Read more about patents. ↗ | |

Tags

Cancer

Wikipedia

Dactinomycin ↗

DrugBank

Dactinomycin ↗

Summary of evidence and Expert Committee recommendations

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for dactinomycin on the complementary list of the EML and EMLc for use in treatment protocols for rhabdomyosarcoma was specifically endorsed. The relevant extracts from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for rhabdomyosarcoma is attached.

[Expert Committee report](#) 
